Bronchiolitis obliterans syndrome (BOS) is the main and late chronic complication after lung transplantation. It remains a major impediment to long-term outcome. Unfortunately, the survival rate of lung transplant recipients lags behind that of other organ transplant recipients, and BOS accounts for more than 30% of all mortality after the third year following lung transplantation. Most recent studies suggest that immune injury is the main pathogenic event in small airway obliteration and the development of BOS. Early detection of BOS is possible as well as essential because prompt initiation of treatment may halt the progress of the disease and the development of chronic graft failure. Current treatment of BOS is disappointing despite adva...
Overall Goals and Objectives: 1. Understand the risk factors for Bronchiolitis Obliterans Syndrome a...
BACKGROUND: Lung transplant (LTx) recipients have low long-term survival and a high incidence of bro...
WINNING ABSTRACT: BOS is the most important cause of late mortality after LTx. Until 5 years ago, th...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreacti...
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is asso...
Lung transplantation remains the only effective therapeutic option for well-selected patients with e...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following...
Lung transplantation is the treatment of choice for patients with end-stage lung disease. However, l...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipien...
Post-transplant bronchiolitis obliterans, also called bronchiolitis obliterans syndrome, affects up ...
Lung transplantation is currently the only available treatment for endstage lung disease patients. D...
Bronchiolitis obliterans (BO) is a rare, chronic form of obstructive lung disease, often initiated w...
Overall Goals and Objectives: 1. Understand the risk factors for Bronchiolitis Obliterans Syndrome a...
BACKGROUND: Lung transplant (LTx) recipients have low long-term survival and a high incidence of bro...
WINNING ABSTRACT: BOS is the most important cause of late mortality after LTx. Until 5 years ago, th...
Bronchiolitis obliterans syndrome (BOS) remains a major complication after lung transplantation, cau...
Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung alloreacti...
Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is asso...
Lung transplantation remains the only effective therapeutic option for well-selected patients with e...
Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise i...
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following...
Lung transplantation is the treatment of choice for patients with end-stage lung disease. However, l...
Bronchiolitis obliterans syndrome (BOS) is a pulmonary complication of allogeneic hematopoietic cell...
With a prevalence of 34% (55/162 at-risk recipients) and a mortality of 25% (14/55 affected recipien...
Post-transplant bronchiolitis obliterans, also called bronchiolitis obliterans syndrome, affects up ...
Lung transplantation is currently the only available treatment for endstage lung disease patients. D...
Bronchiolitis obliterans (BO) is a rare, chronic form of obstructive lung disease, often initiated w...
Overall Goals and Objectives: 1. Understand the risk factors for Bronchiolitis Obliterans Syndrome a...
BACKGROUND: Lung transplant (LTx) recipients have low long-term survival and a high incidence of bro...
WINNING ABSTRACT: BOS is the most important cause of late mortality after LTx. Until 5 years ago, th...